| Customization: | Available |
|---|---|
| Dosage Form: | Injection |
| Dossier: | Ready |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Meloxicam Injection 15mg/1.5ml |
| Strength | 15mg/1.5ml |
| Packing | 5amps/box |
| Origin | China |
This product is a transparent liquid.
Mobique injection is indicated for the initial and short-term symptomatic treatment of:
- Rheumatoid arthritis:
- Painful osteoarthritis (joint disease, degenerative joint disease) :
- Ankylosing spondylitis.
Usage and dosage:
Intramuscular injections are used only in the first few days of treatment. When continuing treatment, the drug should be given orally (in tablets or capsules).
Depending on the intensity of the pain and the severity of the inflammation, the recommended injection dose is 7.5mg or 15mg. Once a day.
This product should be administered by deep intramuscular injection.
Due to possible incompatibility, this product should not be mixed with other drugs in the same syringe.
The maximum daily dose of this product should not be higher than 7.5mg in patients with severe renal failure undergoing hemodialysis.
This product is strictly prohibited for intravenous administration.
Because the dosage for children and adolescents has not been determined, the injection should be limited to adults.
Matters needing attention:
As with other NSAIDs, people with a history of gastrointestinal disease should be treated with caution. Patients with gastrointestinal symptoms should be monitored. If peptic ulcer or gastrointestinal bleeding occurs, use of this product should be discontinued.
It is the same as other NSAIDs with or without premonitoringsymptoms or severe gastrointestinal history. Potentially fatal gastrointestinal bleeding, ulcers, or perforations can occur at any time during treatment, and the consequences of these events are often more severe in the elderly. Special attention should be paid to patients with cutaneous and mucosal adverse reactions, and the use of this product should be considered.
NSAIDs inhibit the synthesis of nephroprostatic turbulence, which plays a supportive role in maintaining renal perfusion. In patients with reduced renal flow and blood volume, the administration of NSAIDs can promote the occurrence of renal decompensation. However, after stopping NSAIDs, kidney function usually returns to pre-treatment levels.
The following patients are at highest risk for these reactions: elderly patients, patients with dehydration, patients with congestive heart failure, patients with cirrhosis, patients with nephrotic syndrome and obvious kidney disease, patients who are taking diuretics, ACE inhibitors, or angiotensin II receptor antagonists at the same time, and patients with reduced blood volume due to major surgery. At the beginning of treatment, the urine volume and kidney function of these patients should be closely monitored.
In rare cases. NSAIDs can cause interstitial nephritis, glomerulonephritis, medullary necrosis of the kidney, or nephrotic syndrome.
As with most NSAIDs, occasional elevations in serum transaminases or other indicators of liver function have been reported. Most cases are minor and temporarily above the normal range. If the abnormality is significant or persistent, the product should be discontinued and followed up.
Patients with clinically stable cirrhosis do not need to decrement.
Patients who are weak or tired are less tolerant of adverse reactions and should be closely monitored.
Same as other NSAIDs. When treating elderly patients, such patients are more likely to have kidney, liver and heart function impairment, and medication should be cautious.
Use of NSAIDs may cause sodium, potassium, and water retention and interfere with diuretic sodium excretion. As a result, susceptible patients may develop or worsen heart failure or high blood pressure.
As with other NSAIDs, meloxicam may mask symptoms of infectious disease. The use of meloxicam in combination with any drug that inhibits cyclooxygenase/prostaglandin synthesis can impair the ability to fertilize and is therefore not recommended for use in women preparing for pregnancy. Therefore, women who are unable to become pregnant or are under investigation for infertility should consider stopping meloxicam. The effects of this drug on the ability to drive vehicles and operate machinery have not been specifically studied. Visual impairment occurs. Patients with narcolepsy or other central nervous system disorders should avoid these behaviors.
){kind=link}